……..catching up on FDA approvals The FDA approved a new ORAL therapy, Ogsiveo (nirogacestat) to SpringWorks Therapeutics Inc., for adult patients with progressing desmoid tumors
Let’s see if we can get your attention…… “The market structure we have right now—three big PBMs dominating the market—will probably not be the one
……catching up on FDA approvals The FDA approved an oral therapy, Zurzuvae (zuranolone) from Biogen Inc./ Sage Therapeutics, Inc.) Zurzuvae is a neuroactive steroid gamma-aminobutyric
The FDA recently approved a new therapy, Omvoh (mirikizumab-mrkz) from Eli Lilly and Company, for the treatment of moderately to severely active ulcerative colitis (UC)
Mark Cuban can now be called a pharmacy trend setter. We’ve read about his cost-plus drugs model….. and it seems that Express Scripts (ESI) feels
…………catching up on FDA approvals The FDA has approved a new therapy, Wezlana (ustekinumab-auub) from Amgen, Inc., as a biosimilar to Janssen Biotech’s Stelara. Wezlana is
Here’s an interesting new twist on hospitals and health systems opening their own specialty pharmacies….. PA-based Geisinger Clinic and NY-based Bassett Healthcare are getting hitched to
There was a big development for DMA patients last June with the FDA approval of Elevidys (delandistrogene moxeparvovec-rokl) from Sarepta Therapeutics. Elevidys was the first and
I always enjoy news about innovative developments in pharmacy. The article below tickled our interest. The article details how Texas A&M has successfully developed a
When a Fortune 100 company breaks the mold on anything it is news. Recently, Tyson Foods made a mold-breaking move and showed it was not averse
